Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrogen Inhalation Therapy in Moderate Covid-19
NCT04633980Phase 1Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Molecular hydrogen in coronavirus disease 2019 (COVID-19), sponsored by CHU Grenoble Alpes. Primary endpoint: Adverse Events. Started Dec 2020; status: completed.
02
Drugs
Molecular hydrogen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04633980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633980.